​
​

Enlivex Therapeutics Stock (NASDAQ:ENLV)

ForecastOwnershipFinancialsChart
Enlivex Therapeutics by TradingView

Previous Close

$1.54

52W Range

$1.15 - $4.59

50D Avg

$1.32

200D Avg

$2.12

Market Cap

$32.32M

Avg Vol (3M)

$61.66K

Beta

1.03

Div Yield

-

ENLV Company Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

71

IPO Date

Jul 31, 2014

Website

ENLV Performance

ENLV Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-24.93M$-25.80M$-19.29M
Net Income$-29.07M$-42.41M$-9.65M
EBITDA$-24.09M$-18.94M$-23.77M
Basic EPS$-1.56$-2.31$-0.54
Diluted EPS$-1.56$-2.31$-0.54

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
CKPTCheckpoint Therapeutics, Inc.
PPBTPurple Biotech Ltd.
PMVPPMV Pharmaceuticals, Inc.
ARDSAridis Pharmaceuticals, Inc.
GMDAGamida Cell Ltd.
ALDXAldeyra Therapeutics, Inc.
APVOAptevo Therapeutics Inc.
MRUSMerus N.V.
HSTOHistogen Inc.
PLURPluri Inc.
IPSCCentury Therapeutics, Inc.
CLGNCollPlant Biotechnologies Ltd.
PHIOPhio Pharmaceuticals Corp.
BLRXBioLineRx Ltd.
CRVSCorvus Pharmaceuticals, Inc.
KROSKeros Therapeutics, Inc.
VCELVericel Corporation